Why Mast Cell Problems and Endometriosis Travel Together
2026-10-31Same post, two depths. Switch any time; the research version has the enzyme names, lab markers, and doses. Written from a research and education perspective: a model of what may be going on and what the published literature suggests would address it if the model is right, not medical advice or a treatment plan.
Print the one-page card (PDF): the levers, up front, on a single sheet.
Wallet-size medical information card to fill in with your clinician: mast cell activation (10-up sheet) · POTS + MCAS + hypermobility (10-up sheet).
A pattern I cannot stop noticing: a huge share of the people with mast cell activation I have worked with (the flushing, hives, food reactions, racing heart after meals) also have endometriosis, and a huge share of the endometriosis cases I have worked through, once I ask the right questions, turn out to have mast cell problems. Most of them have never been told the two are connected. They have a gynecologist for one and an allergist for the other, and neither has heard of the other's diagnosis.
I think they are two faces of the same thing. Let me show you the loop, because once you see it, the lever plan for one turns out to be most of the lever plan for the other.
If the model is right: the levers, up front
- Four weeks low-histamine, and notice what your period does.
- Cruciferous vegetables and fiber every day, because that is how estrogen leaves the body.
- Magnesium, then apigenin at night, then PEA, then NAC, in that order. All four have real data in endometriosis or mast cells or both.
- Clear estrogen properly: spare your methylation budget (creatine and phosphatidylcholine) and fix your gut so estrogen is not recycled.
- Melatonin at bedtime, 3 to 10 mg, which has a real trial for endometriosis pain.
- Get the right tests: plasma heparin and urinary prostaglandin metabolites for the mast cells, an estrogen metabolite panel, and a stool test for the enzyme that recycles estrogen.
- If you are bendy, know that hypermobility, mast cells, and endometriosis come as a set, and address the set.
What endometriosis actually is
Endometriosis is tissue that looks like the lining of the uterus growing where it should not: on the ovaries, the bowel, the bladder, the lining of the pelvis. Every month it bleeds with no exit. The standard story is that it is a hormone problem (estrogen feeds it) and a surgical problem (cut it out).
Both are true and both miss something. When you look at an endometriosis lesion under a microscope, it is packed with mast cells. More mast cells than normal tissue, and they are activated, spilling their contents. The lesions are also full of new nerve fibers that have grown into them, which is why the pain is so far out of proportion to the size of the lesion. And the thing that makes nerves sprout into tissue is a chemical called nerve growth factor, which mast cells release.
So an endometriosis lesion is not just a hormone-fed patch of tissue. It is a mast cell nest with its own nerve supply.
What mast cells do with estrogen
Mast cells have estrogen receptors on their surface. Estrogen lowers their threshold, so the same trigger that would do nothing in week one of your cycle sets them off in week three. This is why so many women with mast cell problems flare before their period, and why they flush and react more in perimenopause when estrogen swings wildly.
It runs the other way too. Histamine, the main chemical mast cells release, stimulates the ovaries to make more estrogen. And the inflammatory chemicals mast cells release switch on the enzyme that makes estrogen locally, right inside the lesion, so the lesion feeds itself even when your blood estrogen looks normal.
Estrogen raises histamine. Histamine raises estrogen. That is the loop.
Why the loop does not shut off
Your body has two ways to get out of this loop, and in the people I have worked with both are usually broken.
Clearing histamine is a methylation job. Inside your cells, histamine is broken down by an enzyme that spends a methyl group every time. Estrogen is also cleared by a methylation enzyme (the same one that clears adrenaline). When your methylation budget is overdrawn, which it is in most of the mast cell cases I have worked through and almost all of my hypermobile ones, both histamine and estrogen hang around longer. I wrote about methylation debt in my connective tissue post here.
Clearing estrogen is a gut job. The liver packages used estrogen and sends it to the gut to leave. Certain gut bacteria make an enzyme that unwraps the package and sends the estrogen back into circulation. When the gut is out of balance, and it is in every mast cell person I have ever tested, estrogen gets recycled instead of excreted. Those same bacteria make histamine, too.
The bendy connection
Hypermobile women have endometriosis at a much higher rate than average, and they have mast cell problems at a much higher rate than average. I do not think that is three separate bits of bad luck. Loose connective tissue means more mast cells in the tissue (they live in connective tissue), more retrograde flow during periods (the tissue that should hold things in place is lax), and the same methylation debt that lets histamine and estrogen pile up. If you are bendy and you have painful periods, assume mast cells are involved until proven otherwise.
What the model predicts would help, and why
1. Diet
Four weeks low-histamine, timed across one full cycle. Cut leftovers older than a day, aged cheese, cured meat, wine and beer, vinegar, fermented foods, tomatoes, spinach, eggplant. Cook fresh and freeze the same day. Watch what happens to the week before your period. For a lot of the people I have worked with, this alone changes the cramps, the bloating, and the flushing.
Cruciferous vegetables every day. Broccoli, cauliflower, cabbage, Brussels sprouts, kale, a cup or more. They push estrogen down the safer clearance route and switch on the liver's packaging enzymes.
Fiber, 25 to 35 grams. Vegetables, beans, flax, berries. Fiber is what carries packaged estrogen out. If you are not having a bowel movement every day, estrogen is being recycled; my stomach acid post here is where to start.
Protein at every meal and omega-3 fish. Sardines, herring, wild salmon, two or three times a week. Omega-3 fats directly lower the inflammatory prostaglandins that drive the cramps.
Cut the things that feed both sides: alcohol (blocks histamine clearance and raises estrogen), sugar and refined flour (insulin raises estrogen and inflames mast cells), and seed oils (they tilt your fats toward the cramping prostaglandins).
Low-mercury fish only. Mercury is hard on both mast cells and methylation.
2. Supplements, in the order the model suggests
The working rule is supplements as low as possible and food first. Add one a week.
- Magnesium 300 to 400 mg at night (glycinate). Calms mast cells, relaxes uterine muscle, and is the cofactor for the enzyme that clears estrogen. Seeking Health Magnesium Malate by day if energy is an issue.
- Apigenin 50 mg at bedtime. The preferred mast cell stabilizer in this model, and it also blocks the enzyme that makes estrogen locally in lesions. It helps you fall asleep, which is why it goes at night.
- PEA (palmitoylethanolamide) 400 mg two or three times a day. It calms mast cells and the nerves that have grown into the lesions, and it has randomized trials specifically for endometriosis pain. Give it six weeks.
- NAC 600 mg three times a day, three days in a row each week. This odd-sounding schedule comes directly from an Italian trial in which it shrank endometriomas and let a good fraction of women cancel their surgery. It also rebuilds glutathione.
- Omega-3 2 grams of EPA plus DHA with a meal (Carlson).
- Creatine 5 grams and phosphatidylcholine 1,200 to 2,400 mg with food, to free up your methylation budget for clearing histamine and estrogen without taking methyl donors. If you have ever gotten anxious on methylfolate, read my methyl trapping post here.
- B6 as P5P 25 to 50 mg in the morning. It is the cofactor for the enzyme that breaks down histamine in the gut and it supports progesterone, which opposes estrogen.
- Vitamin D3 with K2, to a blood level of 50 to 70. Low D is found in most endometriosis cohorts and D calms mast cells directly.
- Melatonin 3 to 10 mg at bedtime. A randomized trial found 10 mg cut endometriosis pain by about 40 percent and reduced painkiller use. It is also a mast cell stabilizer and an antioxidant in the pelvis.
- Calcium-D-glucarate 500 mg twice a day if a stool test shows high beta-glucuronidase (the estrogen-recycling enzyme). It blocks the enzyme.
- DAO (Seeking Health DAO Block) before meals you cannot control, and luteolin 100 mg by day if daytime flushing and reactions are prominent.
- Curcumin with piperine, 500 mg twice a day, if pain is still the main problem after the above; it has small trials in endometriosis and calms mast cells.
3. Lifestyle
- Track your cycle against your mast cell symptoms for two months. If flushing, hives, reflux, and racing heart peak in the week before your period, you have your answer and you can time the stabilizers accordingly (double the apigenin and PEA that week).
- Lower the chemical load that acts like estrogen. Plastics (BPA, phthalates), fragrance, and some pesticides mimic estrogen and also trigger mast cells. Glass storage, fragrance-free products, organic for the produce you eat most, filtered water.
- Sleep. Melatonin is made in the dark and it is one of your anti-endometriosis hormones. Dark room, consistent bedtime, no screens the last hour.
- Move, gently in the painful week and properly the rest of the month. Strength work two or three times a week lowers circulating estrogen and inflammation. If you are bendy, build strength and stability and do not overstretch.
- Heat on the pelvis during flares, and cold water on the face when a mast cell surge is building.
- Slow breathing twice a day. The calm side of your nervous system is what tells mast cells to stand down.
- Work with your gynecologist on the bridges. Progestin-based options and excision surgery are legitimate tools and nothing here conflicts with them. the model would predict a better outcome when surgery is done once, by an excision specialist, on a body whose mast cells have been calmed first.
The sequence the model predicts
The low-histamine trial and magnesium usually show up in the first cycle. PEA, NAC, and melatonin take six to twelve weeks. Estrogen clearance improves over two or three cycles as the gut and the methylation budget recover. The mast cell flares before your period are usually the first thing to shrink, and the cramps follow.
Educational content written from a research perspective, not medical advice. I am a PhD scientist, not a physician, and I do not diagnose, treat, cure, or prevent disease. What you have read is a model of what might be going on and what the published research suggests would address each piece if the model is right. Please take anything you want to try to your own healthcare provider, especially if you take prescription medication or have kidney, liver, or heart disease.
Framing
Endometriosis is usually taught as an estrogen-dependent, surgically managed disease. Mast cell activation syndrome is usually taught as an allergist's diagnosis. In my research consulting work the two co-occur so often that I now ask every person with endometriosis about mast cell symptoms and every person with MCAS about pelvic pain history, and I think the co-occurrence is mechanistic rather than coincidental.
The model: endometriotic lesions are mast cell-rich, mast cell-activated, and mast cell-innervated tissue. Estradiol lowers the mast cell degranulation threshold through ER-beta and GPER; mast cell mediators (histamine, tryptase, PGD2, PGE2, NGF, TNF-alpha, IL-6) drive local aromatase expression, lesion angiogenesis, nerve sprouting, and pain. Histamine and mast cell cytokines in turn raise ovarian and lesional estrogen synthesis. The loop is sustained because the two exit routes, hepatic and intracellular clearance of estrogen and histamine (COMT, HNMT, both SAMe-dependent; UGT and SULT) and gut excretion (estrobolome beta-glucuronidase), are impaired in the same people I have worked with. Connective tissue laxity enriches for all three features.
1. The lesion as a mast cell nest
Mast cell density is increased in peritoneal, ovarian, and deep infiltrating endometriosis compared with eutopic endometrium and with control peritoneum, with a higher proportion of degranulated cells and tryptase-positive cells in close proximity to nerve fibers. Lesional mast cells express ER-alpha, ER-beta, and GPER; estradiol induces degranulation and NGF release in a dose-dependent manner in vitro, and ER antagonists block it.
The consequences for the lesion:
- Nerve sprouting and pain. Mast cell-derived NGF drives the ingrowth of sensory and sympathetic fibers into lesions; nerve fiber density in lesions correlates with pain scores better than lesion size or stage does. Tryptase activates PAR-2 on those fibers, lowering thresholds; histamine at H1 and H4 and PGE2 at EP receptors sensitize them further. This is the peripheral generator for the central sensitization that explains why pain persists after excision in a subset.
- Local estrogen synthesis. IL-6, TNF-alpha, and PGE2 from mast cells and macrophages induce aromatase (CYP19A1) and steroidogenic acute regulatory protein in lesional stromal cells, so lesions synthesize estradiol in situ. PGE2 is the strongest known inducer of aromatase in endometriotic stroma. Circulating estradiol therefore under-represents what the lesion sees.
- Angiogenesis and fibrosis. Mast cell heparin, VEGF, and tryptase support lesion vascularization; tryptase and chymase activate fibroblasts and MMPs, driving the fibrotic, adhesive phenotype.
- Progesterone resistance. Inflammatory signaling downregulates PR-B in lesions, which is why progestins work incompletely and why the inflammatory arm has to be treated alongside the hormonal one.
2. The reverse arm: mediators raise estrogen
Histamine stimulates ovarian estradiol secretion through H1 receptors on granulosa cells, and mast cells are resident in the ovary, where they cluster around follicles and the corpus luteum. Histamine also drives uterine contractility and dysmenorrhea directly. Mast cell-derived IL-6 and TNF-alpha induce aromatase in adipose and lesional tissue systemically. The net effect is that mast cell activation raises estrogen tone, and estrogen raises mast cell activity: a positive feedback loop with no intrinsic brake.
3. Why the brake fails
Shared clearance through methylation
Intracellular histamine is cleared by HNMT, and catechol estrogens (2-OH and 4-OH estradiol) are cleared by COMT. Both are SAMe-dependent methyltransferases, both are magnesium-dependent, and both compete with GAMT, PEMT, and the DNA methyltransferases for the same pool. COMT V158M (slow) is over-represented in the endometriosis cases I have worked through and in the hyperadrenergic MCAS phenotype. When methylation is in debt, as I set out in the connective tissue post here, histamine persists, catechol estrogens persist (and the 4-OH species, unmethylated, forms DNA-reactive quinones), and the hyperadrenergic state from slow catecholamine clearance adds a third stressor.
Shared clearance through the gut
Hepatic phase II conjugates estrogens (glucuronidation by UGT1A1 and UGT2B7, sulfation by SULT1E1) and excretes them in bile. Gut bacteria carrying beta-glucuronidase (notably Clostridia, Bacteroides, and E. coli strains) deconjugate them and return free estrogen to circulation. Endometriosis cohorts show reduced microbial diversity, enrichment of beta-glucuronidase-producing taxa, and LPS elevation; LPS via TLR4 is itself a mast cell and macrophage activator and an aromatase inducer. Several of the same taxa produce histamine. I see dysbiosis in effectively every MCAS person and in the majority of endometriosis people I have worked with, and I read the gut as the shared exit that has been closed.
Connective tissue laxity
Hypermobile EDS and HSD cohorts show substantially higher rates of endometriosis and of mast cell activation than the general population. Mast cells are connective tissue-resident cells and mast cell density scales with connective tissue mass and turnover. Pelvic connective tissue laxity plausibly increases retrograde menstruation and reduces clearance of refluxed tissue; the methylation debt and ROS load that accompany laxity sustain both the mast cell and the estrogen arms. In a hypermobile person with dysmenorrhea the model assumes mast cell involvement until shown otherwise.
Xenoestrogens
Bisphenols, phthalates, and several organochlorine pesticides are ER ligands, aromatase modulators, and direct mast cell degranulators in vitro. They add load to both arms at once.
Markers that would test the model
- Mast cell: plasma heparin (a positive in the people I have worked with far more often than tryptase), urinary 11-beta-PGF2-alpha and 2,3-dinor-11-beta-PGF2-alpha, N-methylhistamine (24-hour, refrigerated, ideally drawn in the luteal week), chromogranin A; serum tryptase interpreted cautiously
- Estrogen metabolism: urinary estrogen metabolite panel (2-OH, 4-OH, 16-OH, and 2-methoxy ratios; a DUTCH-type panel) in the luteal phase; estradiol, progesterone, SHBG day 19 to 22
- Gut: comprehensive stool analysis with beta-glucuronidase activity, calprotectin, zonulin, SCFAs; breath test for SIBO when bloating dominates
- Methylation: homocysteine, methylmalonic acid, RBC folate, SAMe:SAH where available; RBC magnesium
- 25-OH vitamin D; omega-3 index; ferritin (menorrhagia); hs-CRP; CA-125 as a rough lesion-burden marker
- Imaging and surgical staging through gynecology; transvaginal ultrasound with a sonographer trained in deep endometriosis
- Beighton score and a connective tissue history in every person
- Genotype where it changes management: COMT V158M, HNMT C314T, AOC1, MTHFR, CYP1B1 (4-hydroxylation), CYP19A1, UGT1A1, SULT1E1, ESR1
What the model predicts: addressing each node
The target is to break the loop at every node: lower mast cell mediator release, reduce lesional estrogen synthesis and systemic estrogen exposure, reopen both clearance routes, and desensitize the nerves that have grown into the lesion. Hormonal suppression and excision remain legitimate tools and are coordinated with gynecology; the aim is to have the inflammatory arm controlled before and after surgery so the lesion field is less hospitable to recurrence.
Diet
- Histamine restriction across one full cycle, then systematic reintroduction. Aged, fermented, cured, and leftover foods; alcohol; vinegar; tomato, spinach, eggplant. Cook fresh and freeze same day.
- Cruciferous vegetables 1 to 2 cups daily and alliums: indole-3-carbinol and sulforaphane shift estrogen hydroxylation toward 2-OH and induce UGT and GST.
- Fiber 25 to 35 g with emphasis on soluble and fermentable fiber (flax, psyllium, legumes) to bind conjugated estrogens and support butyrate producers. A daily bowel movement is non-negotiable; see the stomach acid post here.
- Omega-3 2 to 3 g EPA plus DHA from small oily fish or supplement, with a meal: competes with arachidonic acid for COX-2, lowering PGE2 and PGF2-alpha, with cohort data linking higher omega-3 intake to lower endometriosis incidence.
- Remove alcohol (inhibits DAO and HNMT, raises estradiol, fragments sleep), refined sugar and flour (insulin lowers SHBG and raises free estradiol; glycation primes mast cells), and industrial seed oils (linoleic load for the 2-series prostaglandins).
- Low-mercury fish selection; mercury impairs both mast cell regulation and methylation.
- Protein 1.2 to 1.6 g/kg for conjugation substrate (glycine, taurine, cysteine, glucuronic acid pool).
Supplements, in the order the model suggests
One agent per week.
- Magnesium glycinate 300 to 400 mg at night: mast cell stabilization, myometrial relaxation, COMT and HNMT cofactor.
- Apigenin 50 mg at bedtime: inhibits mast cell degranulation and IL-6, TNF-alpha, and PGD2 release; inhibits aromatase in vitro; CD38 inhibition sparing NAD+; mild GABA-A activity supporting sleep. Luteolin 100 mg by day where daytime reactivity is prominent; luteolin also inhibits aromatase and has in vitro and rodent data against endometriotic cell proliferation.
- Palmitoylethanolamide 400 mg two to three times daily (micronized or ultramicronized). PPAR-alpha agonist that down-regulates mast cell and microglial activation and reduces NGF-driven sensitization; randomized and open-label trials in endometriosis-associated pelvic pain show meaningful pain reduction, often combined with polydatin. Six-week onset.
- N-acetylcysteine 600 mg three times daily, three consecutive days per week, after the Porpora sequence: in that open-label trial, three months of NAC reduced endometrioma size, pain, and cancellation of scheduled surgery in a substantial fraction compared with controls. Mechanism is glutathione repletion plus inhibition of proliferation and inflammatory signaling.
- Methyl-sparing support before any methyl donor: creatine 5 g and phosphatidylcholine 1,200 to 2,400 mg with food, freeing SAMe for COMT and HNMT. Non-methylated B complex with folinic acid and riboflavin-5-phosphate from quarter dose; see the methyl trapping post here.
- Pyridoxal-5-phosphate 25 to 50 mg in the morning: DAO and HDC cofactor, supports progesterone receptor function and luteal progesterone.
- Vitamin D3 to a 25-OH-D of 50 to 70 ng/mL with K2: deficiency is common in endometriosis cohorts; calcitriol suppresses mast cell activation and lesional inflammatory signaling.
- Melatonin 3 to 10 mg at bedtime: a randomized placebo-controlled trial of 10 mg in endometriosis reduced daily pain by roughly 40 percent and analgesic use by about 80 percent, with improved sleep; melatonin is also a mast cell stabilizer, an antioxidant, and a modest aromatase and ER modulator.
- Calcium-D-glucarate 500 mg twice daily when stool beta-glucuronidase is elevated; it inhibits the enzyme and reduces estrogen recirculation.
- DAO 10,000 to 20,000 HDU before uncontrolled meals; curcumin with piperine 500 mg twice daily as a second-tier anti-inflammatory with small trials in endometriosis and mast cell stabilizing activity; resveratrol 400 mg where aromatase activity appears high, with the caution that it is a mild estrogen receptor modulator.
- Iron bisglycinate every other day with vitamin C when ferritin is under 50, which is common with menorrhagia.
The model argues against aggressive DIM in this picture; the 2-OH shift is useful, but DIM can lower estrogen enough to worsen mast cell symptoms in perimenopausal people I have worked with and the gentler route is crucifers, fiber, and glucarate first.
Lifestyle
- Cycle-mapped symptom tracking for two cycles, logging mast cell symptoms against cycle day. Luteal peaking confirms the estrogen-mast cell coupling and allows pre-emptive dosing (doubling apigenin and PEA from day 18).
- Xenoestrogen and mast cell trigger reduction: glass or stainless storage, no heated plastic, fragrance-free personal and cleaning products, organic for high-residue produce, filtered water, HEPA filtration in the bedroom.
- Sleep and darkness: endogenous melatonin is produced in darkness and suppressed by evening light; fixed schedule, dark room, no screens in the last hour.
- Resistance training two to three times weekly lowers circulating estradiol and inflammatory tone and raises SHBG; in hypermobile people I have worked with, stability work without end-range stretching. Gentle movement only in the painful week.
- Vagal tone: slow breathing at 5 to 6 breaths per minute twice daily; cold-water face immersion for acute mast cell surges; local heat for pelvic pain.
- Where prescribed medications fit. Progestins, combined contraceptives, GnRH analogues, and H1 and H2 antihistamines or cromolyn are bridges that act on single arms of the loop and do not conflict with this sequence. Excision by a specialist surgeon remains the definitive approach for established disease; the model would predict better outcomes when the mast cell arm is quiet for at least one cycle before surgery and kept quiet afterward, because the lesion field and its mast cells are what drive recurrence.
Markers to follow, and the sequence the model predicts
Cycle-mapped symptom scores monthly; mast cell markers and estrogen metabolite panel at three months; stool analysis at three to six months. Histamine restriction and magnesium change the luteal mast cell flare within one cycle; PEA, NAC, and melatonin change pain over six to twelve weeks; estrogen metabolite ratios and beta-glucuronidase respond over two to three cycles as the gut and the methylation budget recover. The premenstrual mast cell flare is usually the first thing to shrink; dysmenorrhea follows.
Educational and research content, not medical advice. The author holds a PhD in cellular and molecular nutrition, is not a licensed physician, and does not diagnose, treat, cure, or prevent disease. The sequences described are what this model predicts would address each node if the model is correct, with the supporting literature cited in the text; they are offered for discussion with a qualified clinician, who should manage any agent with contraindications or interactions.
